BIMI International Medical Inc. (BIMI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BIMI International Medical Inc. (BIMI) trades at $0.0001 with AI Score 42/100 (Grade C). BIMI International Medical Inc. operates in the retail and wholesale distribution of medical devices, pharmaceuticals, and healthcare products within the People's Republic of China. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BIMI: BIMI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIMI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BIMI: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
BIMI International Medical Inc. (BIMI) Healthcare & Pipeline Overview
BIMI International Medical Inc. focuses on the distribution of medical devices, pharmaceuticals, and healthcare products in China, operating through wholesale and retail channels. The company offers a range of products, including pharmaceuticals, medical devices, and traditional Chinese medicines, primarily serving the Southwest region of China.
What Is the Investment Thesis for BIMI?
BIMI International Medical Inc. presents a speculative investment opportunity within the Chinese healthcare market, contingent on successful execution of its distribution and service strategies. The company's diverse operations across wholesale pharmaceuticals, medical devices, retail pharmacies, and medical services provide multiple revenue streams. However, its negative profit margin of -189.3% raises concerns about its financial stability. Growth catalysts include expanding its distribution network and enhancing its medical service offerings. Key risks include navigating regulatory complexities in the Chinese healthcare market and achieving profitability. Investors should closely monitor the company's ability to improve its financial performance and capitalize on market opportunities.
Based on FMP financials and quantitative analysis
BIMI Key Highlights
- BIMI operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies, providing diversification.
- Distributes Stryker spinal products and Olympus endoscopes, indicating partnerships with established medical device manufacturers.
- Operates retail pharmacies under the Lijiantang Pharmacy brand, offering a range of healthcare products.
- Profit margin of -189.3% indicates significant financial challenges.
- Market capitalization of $0.00B reflects its small size and potential volatility.
Who Are BIMI's Competitors?
BIMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HEWA HealthWarehouse.com, Inc. | $0.12 | -0.08% | $5.11M | 55 |
| MSLE Satellos Bioscience Inc. Common Stock | $8.35 | -6.70% | $10.8M | 43 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.3M | 63 |
| YI 111, Inc. | $3.77 | +3.86% | $32.9M | 44 |
| MYCOF Noveris Health Sciences Inc. | $1.15 | +4.55% | $67.3M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.15 | -0.23% | $189M | 47 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIMI's Key Strengths?
- Established distribution network in Southwest China.
- Partnerships with reputable medical device manufacturers.
- Diverse product portfolio.
- Presence in both wholesale and retail channels.
What Are BIMI's Weaknesses?
- Negative profit margin.
- Limited geographic reach beyond Southwest China.
- Dependence on third-party suppliers.
- Small market capitalization.
What Could Drive BIMI Stock Higher?
- Expansion of the Lijiantang Pharmacy retail network to new locations within China.
- Efforts to secure additional distribution agreements with medical device manufacturers.
- Development of new medical service offerings within existing hospital facilities.
What Are the Key Risks for BIMI?
- Financial-distress signal — its Altman Z-Score of -3.54 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory changes in the Chinese healthcare market could impact operations and profitability.
- Intense competition from established domestic and international players.
- Fluctuations in currency exchange rates could affect financial performance.
- The company's negative profit margin poses a risk to its long-term financial stability.
- Limited liquidity due to OTC Other market trading.
What Are the Growth Opportunities for BIMI?
- Expansion of Medical Service Offerings: BIMI can expand its medical service offerings within its hospitals to attract more patients and generate additional revenue streams. This includes investing in advanced medical technologies and expanding the range of specialized medical services offered. The Chinese medical services market is projected to reach $1.5 trillion by 2028, presenting a substantial growth opportunity for BIMI. Timeline: Ongoing.
- Geographic Expansion within China: BIMI can extend its distribution network beyond the Southwest region of China to other high-growth areas. This involves establishing new partnerships with hospitals, clinics, and pharmacies in different regions. The Chinese pharmaceutical market is expected to grow at a CAGR of 7% over the next five years, providing a favorable environment for geographic expansion. Timeline: 2-3 years.
- Development of Proprietary Healthcare Products: BIMI can invest in the research and development of its own proprietary healthcare products, including generic drugs and traditional Chinese medicines. This would allow the company to increase its profit margins and differentiate itself from competitors. The global market for generic drugs is projected to reach $470 billion by 2027. Timeline: 3-5 years.
- Enhancement of Retail Pharmacy Network: BIMI can enhance its retail pharmacy network under the Lijiantang Pharmacy brand by opening new stores and improving the customer experience. This includes offering a wider range of products, providing personalized healthcare advice, and implementing digital solutions. The Chinese retail pharmacy market is expected to grow at a CAGR of 8% over the next five years. Timeline: Ongoing.
- Strategic Partnerships with International Healthcare Companies: BIMI can form strategic partnerships with international healthcare companies to distribute their products in China or to collaborate on research and development projects. This would provide access to new technologies, products, and markets. The increasing globalization of the healthcare industry presents opportunities for such partnerships. Timeline: 1-2 years.
What Opportunities Does BIMI Have?
- Expansion into new geographic markets within China.
- Development of proprietary healthcare products.
- Strategic partnerships with international healthcare companies.
- Increasing healthcare expenditure in China.
What Threats Does BIMI Face?
- Intense competition from domestic and international players.
- Stringent regulatory requirements in the Chinese healthcare market.
- Fluctuations in currency exchange rates.
- Economic slowdown in China.
What Are BIMI's Competitive Advantages?
- Established distribution network in the Southwest region of China.
- Partnerships with established medical device manufacturers like Stryker and Olympus.
- Retail pharmacy network under the Lijiantang Pharmacy brand.
- Diverse product portfolio including medical devices, pharmaceuticals, and traditional Chinese medicines.
What Does BIMI Do?
BIMI International Medical Inc., originally incorporated in 2000 and based in Chongqing, China, is a multifaceted healthcare company engaged in the distribution of medical devices, pharmaceuticals, and other healthcare products. The company operates through four key segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. BIMI distributes a variety of products, including Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment, targeting drug stores, private clinics, pharmaceutical dealers, and hospitals, particularly in the Southwest region of China. In addition to distributing branded medical equipment, BIMI also deals in generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. The company's retail operations are conducted under the Lijiantang Pharmacy brand, offering prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items. BIMI also provides medical services through its hospitals and IT research and development services. The company changed its name from BOQI International Medical Inc. to BIMI International Medical Inc. in June 2021, reflecting its ongoing evolution and strategic focus within the healthcare sector.
What Products and Services Does BIMI Offer?
- Wholesale distribution of medical devices.
- Wholesale distribution of pharmaceuticals.
- Operation of retail pharmacies under the Lijiantang Pharmacy brand.
- Provision of medical services through hospitals.
- Distribution of Stryker spinal products and Olympus endoscopes.
- Distribution of generic drugs and traditional Chinese medicines.
- IT research and development services.
How Does BIMI Make Money?
- Generates revenue through the wholesale distribution of medical devices and pharmaceuticals to hospitals, clinics, and pharmacies.
- Earns revenue from the retail sale of prescription and over-the-counter drugs, health foods, and medical devices through its Lijiantang Pharmacy stores.
- Provides medical services in hospitals, generating revenue from patient care and related services.
What Industry Does BIMI Operate In?
BIMI International Medical Inc. operates within the rapidly growing Chinese healthcare market, driven by increasing healthcare expenditure and an aging population. The market is characterized by intense competition among domestic and international players. BIMI's focus on distributing medical devices and pharmaceuticals positions it within a critical segment of the healthcare supply chain. The company faces competition from established distributors and retailers, including ADYX, BGMD, CFRXQ, DMKPQ, and EFTR. Success depends on navigating regulatory hurdles, building strong relationships with suppliers and customers, and adapting to evolving market trends.
Who Are BIMI's Key Customers?
- Drug stores in the People's Republic of China.
- Private clinics in the People's Republic of China.
- Pharmaceutical dealers in the People's Republic of China.
- Hospitals in the People's Republic of China.
Key Financial Metrics
Return on assets is -62.7%, showing how much profit it generates from its asset base. A current ratio of 0.92 means current liabilities exceed short-term assets, a liquidity point worth watching.
BIMI International Medical Inc. (BIMI) Valuation Context
Relative to its peer group, BIMI's quantitative score of 42/100 is roughly in line with the peer average of 51/100.
Company Profile
BIMI International Medical Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Chongqing, CN. The company is led by CEO Tiewei Song. BIMI has traded publicly since 2006.
F-Score 3/9Financial Health
BIMI International Medical Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.54 places it in the distress zone, a signal of elevated financial risk.
BIMI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established distribution network in Southwest China.
- Partnerships with reputable medical device manufacturers.
- Diverse product portfolio.
- Presence in both wholesale and retail channels.
Bear Case
- Negative profit margin.
- Limited geographic reach beyond Southwest China.
- Dependence on third-party suppliers.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BIMI Latest News
No recent news available for BIMI.
BIMI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIMI.
Price Targets
Wall Street price target analysis for BIMI.
BIMI MoonshotScore
What does this score mean?
The MoonshotScore rates BIMI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Tiewei Song
CEO
Tiewei Song serves as the CEO of BIMI International Medical Inc., overseeing the company's strategic direction and operations. Information regarding Mr. Song's detailed career history, educational background, and previous roles is not available. As CEO, he is responsible for managing the company's 296 employees and driving its growth in the Chinese healthcare market.
Track Record: Due to limited information available, it is not possible to provide a comprehensive assessment of Tiewei Song's track record. His leadership is focused on navigating the complexities of the Chinese healthcare market and expanding BIMI's presence in the distribution of medical devices and pharmaceuticals.
BIMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BIMI International Medical Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Distribution agreements with established medical device manufacturers.
- Operation of retail pharmacies under the Lijiantang Pharmacy brand.
- Presence in the Chinese healthcare market since 2000.
- Company size of 296 employees.
- Physical headquarters located in Chongqing, China.
BIMI International Medical Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for BIMI?
BIMI holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. BIMI International Medical Inc. operates in the retail and wholesale distribution of medical devices, pharmaceuticals, and healthcare products within the People's Republic of China. The company's …
What does BIMI International Medical Inc. do?
BIMI International Medical Inc. operates as a distributor and retailer of medical devices, pharmaceuticals, and healthcare products in China. The company's business encompasses wholesale distribution to hospitals, clinics, and pharmacies, as well as retail sales through its Lijiantang Pharmacy stores. BIMI also provides medical services through its hospital facilities. Its product range includes medical devices from brands like Stryker and Olympus, generic drugs, traditional Chinese medicines, and various healthcare-related products.
What do analysts say about BIMI stock?
As of March 17, 2026, there is no available analyst coverage or consensus on BIMI International Medical Inc. due to its OTC listing and small market capitalization. Investors should conduct their own independent research and due diligence before considering an investment in BIMI.
What are the main risks for BIMI?
BIMI International Medical Inc. faces several risks, including intense competition in the Chinese healthcare market, stringent regulatory requirements, and fluctuations in currency exchange rates. The company's negative profit margin poses a significant risk to its financial stability and ability to sustain operations.
What are the key factors to evaluate for BIMI?
BIMI International Medical Inc. (BIMI) holds an AI score of 42/100 (low). Not financial advice.
How frequently does BIMI data refresh on this page?
BIMI's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BIMI's recent stock price performance?
BIMI International Medical Inc. (BIMI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established distribution network in Southwest China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIMI overvalued or undervalued right now?
BIMI International Medical Inc. (BIMI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BIMI before investing?
Before investing in BIMI International Medical Inc. (BIMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO Tiewei Song's background and track record.
- Financial data based on available information and may not be fully comprehensive.
- OTC market investments carry higher risks than exchange-listed stocks.